PharmaEssentia Gets US FDA's Approval for Essential Thrombocythemia Treament Drug; Shares Sink 10%

MT Newswires Live

Yesterday

PharmaEssentia (TPE:6446) has received approval from the US Food and Drug Administration for BESREMi (Ropeginterferon alfa-2b-njft) solution for injection in a pre-filled syringe of 500 mcg/mL and in a pre-filled pen injector 500 mcg/0.5 mL, according to a Friday filing to the Taiwan stock exchange.

The company's shares were down 10% in Monday's trade.

The drug is used in the treatment of adults with essential thrombocythemia and with polycythemia vera, or PV.

Following the approval, PharmaEssentia USA Corporation will start the sales and marketing activities of BESREMi (ropeginterferon alfa-2b) for essential thrombocythemia in the US.

The US FDA approved BESREMi (ropeginterferon alfa-2b-njft) for the treatment of all adults with PV in November 2021.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://au1.tigerplaytime.com/news/2663024641"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2663024641\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2663024641?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-08-31 12:50","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2663024641","market":"hk","top_or_hot":-1,"title":"PharmaEssentia Gets US FDA's Approval for Essential Thrombocythemia Treament Drug; Shares Sink 10%","media":"MT Newswires Live","content":"<html><body><p> PharmaEssentia (TPE:6446) has received approval from the US Food and Drug Administration for BESREMi (Ropeginterferon alfa-2b-njft) solution for injection in a pre-filled syringe of 500 mcg/mL and in a pre-filled pen injector 500 mcg/0.5 mL, according to a Friday filing to the Taiwan stock exchange.</p><p>The company's shares were down 10% in Monday's trade.</p><p>The drug is used in the treatment of adults with essential thrombocythemia and with polycythemia vera, or PV.</p><p>Following the approval, PharmaEssentia USA Corporation will start the sales and marketing activities of BESREMi (ropeginterferon alfa-2b) for essential thrombocythemia in the US.</p><p>The US FDA approved BESREMi (ropeginterferon alfa-2b-njft) for the treatment of all adults with PV in November 2021.</p></body></html>","source":"mtnewswires_news","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>PharmaEssentia Gets US FDA's Approval for Essential Thrombocythemia Treament Drug; Shares Sink 10%</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nPharmaEssentia Gets US FDA's Approval for Essential Thrombocythemia Treament Drug; Shares Sink 10%\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1092851196\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">MT Newswires Live </p>\n<p class=\"h-time\">2026-08-31 12:50</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html><body><p> PharmaEssentia (TPE:6446) has received approval from the US Food and Drug Administration for BESREMi (Ropeginterferon alfa-2b-njft) solution for injection in a pre-filled syringe of 500 mcg/mL and in a pre-filled pen injector 500 mcg/0.5 mL, according to a Friday filing to the Taiwan stock exchange.</p><p>The company's shares were down 10% in Monday's trade.</p><p>The drug is used in the treatment of adults with essential thrombocythemia and with polycythemia vera, or PV.</p><p>Following the approval, PharmaEssentia USA Corporation will start the sales and marketing activities of BESREMi (ropeginterferon alfa-2b) for essential thrombocythemia in the US.</p><p>The US FDA approved BESREMi (ropeginterferon alfa-2b-njft) for the treatment of all adults with PV in November 2021.</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"LABU","symbol_name":"三倍做多标普生物-Direxion","start_time":0,"source_url":"https://www.mtnewswires.com/","article_id":"2663024641","we_media_id":"1092851196","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2663024641","pubTimestamp":1788151819,"columns":[],"sourceInfo":{"source_id":"mtnewswires_news","name":"MT Newswires"},"weMediaInfo":{"media_name":"MT Newswires Live","introduction":"The most recognized names in North America, Europe and Asia rely on MT Newswires to power their applications. Better news, better service, better price.","home_visible":1,"id":"1092851196","head_image":"https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e"},"summary":"PharmaEssentia  has received approval from the US Food and Drug Administration for BESREMi  solution for injection in a pre-filled syringe of 500 mcg/mL and in a pre-filled pen injector 500 mcg/0.5 mL, according to a Friday filing to the Taiwan stock exchange.The company's shares were down 10% in Monday's trade.The drug is used in the treatment of adults with essential thrombocythemia and with polycythemia vera, or PV.Following the approval, PharmaEssentia USA Corporation will start the sales and marketing activities of BESREMi  for essential thrombocythemia in the US.The US FDA approved BESREMi  for the treatment of all adults with PV in November 2021.","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"LABU":"三倍做多标普生物-Direxion","BK4588":"碎股","BK4585":"ETF&股票定投概念"},"translate_title":"PharmaEssentia获得美国FDA批准基本血小板增多症治疗药物；股价下跌 10%","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"LABU":1.5},"content_text":"PharmaEssentia (TPE:6446) has received approval from the US Food and Drug Administration for BESREMi (Ropeginterferon alfa-2b-njft) solution for injection in a pre-filled syringe of 500 mcg/mL and in a pre-filled pen injector 500 mcg/0.5 mL, according to a Friday filing to the Taiwan stock exchange.The company's shares were down 10% in Monday's trade.The drug is used in the treatment of adults with essential thrombocythemia and with polycythemia vera, or PV.Following the approval, PharmaEssentia USA Corporation will start the sales and marketing activities of BESREMi (ropeginterferon alfa-2b) for essential thrombocythemia in the US.The US FDA approved BESREMi (ropeginterferon alfa-2b-njft) for the treatment of all adults with PV in November 2021.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":true,"editions":null,"column":"","sentiment":"-1","news_tag":"productRelease","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":1,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"}}}